XENON PHARMACEUTICALS INC. (XENE) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 45.01M USD | Liabilities, Current |
| Cash and equivalents | 119.53M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 811.16M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $45.01M | $119.53M | $811.16M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $39.81M | $545.87M | $548.88M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $41.79M | $199.16M | $349.72M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $38.34M | $104.51M | $357.75M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $33.05M | $135.38M | $352.16M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $32.03M | $116.66M | $432.97M | (m) | (m) | (m) |
| 2024-12-31 | $628.37M | $35.59M | $142.71M | $484.19M | $1.47M | (m) | 17.66× |
| 2024-09-30 | $654.95M | $29.70M | $87.62M | $566.39M | $938.00K | (m) | 22.06× |
| 2024-06-30 | $722.39M | $31.29M | $136.73M | $584.80M | $853.00K | (m) | 23.09× |
| 2024-03-31 | $700.43M | $22.22M | $58.90M | $640.71M | $833.00K | (m) | 31.52× |
| 2023-12-31 | $638.96M | $27.27M | $148.64M | $489.44M | $874.00K | (m) | 23.43× |
| 2023-09-30 | $527.48M | $24.74M | $99.57M | $427.10M | $805.00K | (m) | 21.32× |
| 2023-06-30 | $541.72M | $28.16M | $64.55M | $475.05M | $2.12M | (m) | 19.24× |
| 2023-03-31 | $529.26M | $22.49M | $69.51M | $457.53M | $2.22M | (m) | 23.53× |
| 2022-12-31 | $593.07M | $22.70M | $57.24M | $534.85M | $986.00K | (m) | 26.12× |
| 2022-09-30 | $640.67M | $15.54M | $103.49M | $534.70M | $2.48M | (m) | 41.23× |
| 2022-06-30 | $790.76M | $13.74M | $369.99M | $418.25M | $2.52M | (m) | 57.57× |
| 2022-03-31 | $540.86M | $7.98M | $116.54M | $421.40M | $2.92M | (m) | 67.76× |
| 2021-12-31 | $554.54M | $14.32M | $175.69M | $376.09M | $2.77M | (m) | 38.72× |
| 2021-09-30 | $252.86M | $12.86M | $87.81M | $161.82M | $3.23M | (m) | 19.67× |
| 2021-06-30 | $263.44M | $14.98M | $82.93M | $177.59M | $2.92M | (m) | 17.58× |
| 2021-03-31 | $279.76M | $11.49M | $87.98M | $186.72M | $5.06M | (m) | 24.34× |
| 2020-12-31 | $178.82M | $14.78M | $45.01M | $131.99M | $1.82M | (m) | 12.10× |
| 2020-09-30 | $192.54M | $16.92M | $15.10M | $175.83M | $1.61M | (m) | 11.38× |
| 2020-06-30 | $204.54M | $21.05M | $44.20M | $158.56M | $1.79M | (m) | 9.71× |
| 2020-03-31 | $231.29M | $48.52M | $60.51M | $169.16M | $1.62M | (m) | 4.77× |
| 2019-12-31 | $142.17M | $43.38M | $24.75M | $116.60M | $813.00K | (m) | 3.28× |
| 2019-09-30 | $94.81M | $11.70M | $37.67M | $56.93M | $209.00K | (m) | 8.11× |
| 2019-06-30 | $101.97M | $9.33M | $37.08M | $64.73M | $171.00K | (m) | 10.93× |
| 2019-03-31 | $110.56M | $6.38M | $52.18M | $58.25M | $132.00K | (m) | 17.34× |
| 2018-12-31 | $119.56M | $4.12M | $67.75M | $51.55M | $256.00K | (m) | 29.03× |
| 2018-09-30 | $127.31M | $4.41M | $87.96M | $39.17M | $180.00K | (m) | 28.85× |
| 2018-06-30 | $63.44M | $3.09M | $47.44M | $15.84M | $171.00K | (m) | 20.50× |
| 2018-03-31 | $35.51M | $3.79M | $17.20M | $17.88M | $432.00K | (m) | 9.37× |
| 2017-12-31 | $44.10M | $4.08M | $20.49M | $23.18M | $438.00K | (m) | 10.80× |
| 2017-09-30 | $43.90M | (m) | $14.69M | $29.08M | $129.00K | (m) | (m) |
| 2017-06-30 | $51.89M | (m) | $23.09M | $28.61M | $198.00K | (m) | (m) |
| 2017-03-31 | $58.22M | (m) | $20.16M | $37.87M | $189.00K | (m) | (m) |
| 2016-12-31 | $64.35M | $3.52M | $17.09M | $47.05M | $200.00K | (m) | 18.30× |
| 2016-09-30 | $70.09M | $3.98M | $54.13M | $15.36M | $595.00K | (m) | 17.63× |
| 2016-06-30 | $51.40M | $2.93M | $35.21M | $15.53M | $658.00K | (m) | 17.55× |
| 2016-03-31 | (m) | $2.87M | $56.06M | (m) | $386.00K | (m) | (m) |
| 2015-12-31 | (m) | $2.78M | $58.65M | (m) | $315.00K | (m) | (m) |
| 2015-09-30 | (m) | $5.34M | $65.47M | (m) | $274.00K | (m) | (m) |
| 2015-06-30 | $73.89M | $12.02M | $64.35M | $9.35M | $188.00K | (m) | 6.15× |
| 2015-03-31 | $76.59M | $10.25M | $65.92M | $9.46M | $1.21M | (m) | 7.47× |
| 2014-12-31 | $84.26M | $14.29M | $72.03M | $12.02M | $215.00K | (m) | 5.90× |
| 2014-09-30 | $48.10M | $16.34M | $33.73M | $14.21M | $162.00K | (m) | 2.94× |
| 2014-06-30 | (m) | (m) | $35.09M | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | $34.95M | (m) | (m) | (m) | (m) |
| 2013-12-31 | $49.72M | $18.20M | $37.95M | $11.33M | $440.00K | (m) | 2.73× |
| 2013-09-30 | (m) | (m) | $43.61M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | $60.16M | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | $13.93M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |